Company intelligence / Profile preview

Kai Medical

Ownership: Private
Development stage: Commercial

Overview

KAI Pharmaceuticals developed selective modulators of protein kinase C isozymes, with a lead compound (KAI‑9803) that completed Phase I/II trials in acute myocardial infarction before being acquired by Amgen in April 2012 for $315 million. The company also worked on therapies for secondary hyperparathyroidism and kidney diseases. Kai BioTech Co., Ltd. is a separate active Korean company focused on radiopharmaceuticals for indications such as dementia and liver cancer.

Therapeutic areas: NephrologyOncologyEndocrinologyCardiovascularNeurology
Modalities: Small moleculePeptidesProteinsRadiopharmaceuticals
Industry: Biotech

Beyond the preview

Go deeper on Kai Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kai Medical.

Explore the full profile